P/E ratio for Corbus Pharmaceuticals (CRBP)
P/E ratio as of July 2025 (TTM): -2.27
According to Corbus Pharmaceuticals 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -2.27251. At the end of 2024 the company had a P/E ratio of -3.22.
P/E ratio history for Corbus Pharmaceuticals from 2015 to 2025
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2024 | -3.22 | |
| 2022 | -0.3278 | -79.25% |
| 2021 | -1.58 | 87.01% |
| 2020 | -0.8446 | -82.52% |
| 2019 | -4.83 | -18.92% |
| 2018 | -5.96 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Vanda Pharmaceuticals VNDA | -6.27 | 175.76% | 🇺🇸 USA |
 Viking Therapeutics
VKTX | -28.9 | 1,170.38% | 🇺🇸 USA |
 Epizyme EPZM | N/A | N/A | 🇺🇸 USA |
 Advaxis ADXS | -0.0050 | -99.78% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.